Cory Renauer
Value, research analyst, biotech, small-cap

Putting Alnylam's Positive ATTR Clinical Data In Context

On Thursday Morning, July 11, Alnylam (NASDAQ:ALNY) shared some very positive data from an ongoing Phase 1 trial of ALN-TTRsc. The market loved the data enough to send its shares soaring 15% before the market opened, where they stayed until the close. After a day to digest the news, the market drove shares even higher, then back to Earth. On Thursday, July 18, shares of Alnylam closed at $42.87, still about 14% higher than its closing price of $37.6 on Wednesday, July 10.

I have to admit I found the initial response to Alnylam's Phase 1 data baffling. Isis Pharmaceuticals (ISIS) is also working on a transthyretin-mediated amyloidosis [ATTR] therapy, and it is much further along....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details